RNA · Forms 3, 4, 5
Insider trades at Atrium Therapeutics, Inc.
No open-market insider buys or sells at Atrium Therapeutics, Inc. in the last 90 days; 8 filings reported awards, option exercises, tax withholding or new insiders.
Every Form 3, 4 and 5 filed for Atrium Therapeutics, Inc. (RNA) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Insider trades in the last 90 days
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Husam Younis | Chief Scientific Officer | Tax withholding | 11,216 | $8.95 | $100K | Form 4 | |
| Steven George Hughes | Chief Medical Officer | Tax withholding | 21,459 | $8.95 | $192K | Form 4 | |
| W. Michael Flanagan | Director | Tax withholding | 22,812 | $8.95 | $204K | Form 4 | |
| Sarah Boyce | Director | Tax withholding | 126,418 | $8.95 | $1.1M | Form 4 | |
| Stephanie Kenney | See Remarks | Tax withholding | 2,375 | $8.95 | $21K | Form 4 | |
| Kathleen P. Gallagher | See Remarks | Tax withholding | 11,632 | $8.95 | $104K | Form 4 | |
| Brendan R. Winslow | Chief Financial Officer | Tax withholding | 6,742 | $8.95 | $60K | Form 4 | |
| Rocio Martin Hoyos | Chief Strategy Officer | Tax withholding | 8,320 | $8.95 | $74K | Form 4 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.